Matinas BioPharma Holdings, Inc. Quarterly report pursuant to Section 13 or 15(d)

Going Concern and Plan of Operations (Details Textual) - USD ($)	3 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Dec. 31, 2015
Going Concern And Plan Of Operation [Line Items]
Deficit accumulated during development stage	$ (25,431,774)		$ (23,187,164)
Net loss	$ (2,244,610)	$ (2,570,111)	$ (9,100,000)

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.